Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļZTS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļZoetis Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 01, 2013
āļāļĩāļāļĩāđāļPeck (Kristin C)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ13800
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 01
āļāļĩāđāļāļĒāļđāđ10 Sylvan Way
āđāļĄāļ·āļāļPARSIPPANY
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ07054
āđāļāļĢāļĻāļąāļāļāđ19738227000
āđāļ§āđāļāđāļāļāđhttps://www.zoetis.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļZTS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 01, 2013
āļāļĩāļāļĩāđāļPeck (Kristin C)
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Ms. Louise M. Parent
Independent Director
Mr. Sanjay Khosla
Independent Director
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Ms. Vanessa Broadhurst
Independent Director
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
Mr. Keith Sarbaugh
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
Mr. Nicholas (Nick) Ashton
Mr. Nicholas (Nick) Ashton
Executive Vice President, President - Global Manufacturing and Supply
Executive Vice President, President - Global Manufacturing and Supply
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Ms. Louise M. Parent
Independent Director
Mr. Sanjay Khosla
Independent Director
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
VanEck Pharmaceutical ETF
iShares U.S. Pharmaceuticals ETF
First Trust NASDAQ Pharmaceuticals ETF
Polen Capital Global Growth ETF
State Street SPDR S&P Pharmaceuticals ETF
AAM Sawgrass US Large Cap Quality Growth ETF
Themes US R&D Champions ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ProShares Pet Care ETF
āļŠāļąāļāļŠāđāļ§āļ9.4%
VanEck Pharmaceutical ETF
āļŠāļąāļāļŠāđāļ§āļ9.02%
VanEck Agribusiness ETF
āļŠāļąāļāļŠāđāļ§āļ7.81%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ4.26%
Honeytree US Equity ETF
āļŠāļąāļāļŠāđāļ§āļ3.86%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ3.58%
Polen Capital Global Growth ETF
āļŠāļąāļāļŠāđāļ§āļ3.35%
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
āļŠāļąāļāļŠāđāļ§āļ2.47%
Themes US R&D Champions ETF
āļŠāļąāļāļŠāđāļ§āļ1.96%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
2.56B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Jun 02, 2026 going ex on Apr 20, 2026
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Mar 03, 2026 going ex on Jan 20, 2026
ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ